Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Benjamin Nwakanme(The University of Texas MD Anderson Cancer Center), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Shilpa Paul(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Monica Kwari(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The Royal Melbourne Hospital), Christopher Loiselle(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), Sa A. Wang(Beijing Institute of Technology), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Heather Schroeder(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine)
Cited by 20
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k